This study checks how safe and tolerable a new drug, SION-719, is when used with Trikafta, a medicine for cystic fibrosis (CF). It will also study how the drug moves and behaves in the body, known as pharmacokinetics and pharmacodynamics. Participants must have a specific type of CF called F508del homozygous genotype and have been taking Trikafta without changes for at least 3 months. They should not have any recent major health problems.
- The study involves adding SION-719 to existing Trikafta treatment.
- Participants must have been stable on Trikafta for at least 3 months.
- People with certain other illnesses or cancer histories may not join.